Ligand Pharmaceuticals (LGND) Key Ratios

$289.50

up-down-arrow $2.56 (0.89%)

As on 20-Nov-2026 12:39EST

Market cap

info icon

$6,177 Mln

Revenue (TTM)

info icon

$254 Mln

P/E Ratio

info icon

124

P/B Ratio

info icon

6.6

Div. Yield

info icon

0 %

Key Ratios and Highlights

Growth Score (%) Quarterly Annual (TTM)
Particulars QoQ YoY 1-Year 3-Years 5-Years
Revenue 23.63 -31.80 1.03 24.90 -1.56
EBIT -164.06 -129.19 -12.91 -17.79 5.03
Net Profit -158.72 -124.29 5.93 46.16 -5.51
EPS -164.24 -125.10 7.91 38.89 -10.87
Book Value -- -- 9.95 10.80 2.50
Key Ratios (%) Average Annual (TTM)
Particulars3-Years5-YearsTTMDec-25Dec-24
EBIT-Margin info 37.2033.7822.6059.293.32
Net Margin info --24.8920.27----
Return on equity info 6.994.755.2513.47-0.53
Return on Capital info 5.923.81--10.79-0.52
Return on Assets info 5.403.452.429.95-0.47
Debt to Equity (x) info ----0.710.440.01
ROCE

--

--

Earning before interest and taxes / (Average net worth + Average total Debt) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
--
10.79
-0.52
7.49
-3.64
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROE

5.25

Lower than Peers by 10.64

Profit after tax / Average Net worth * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
5.25
13.47
-0.53
8.03
-4.70
Peer Median
15.89
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
ROA

2.42

Lower than Peers by 0.26

Profit after tax / Average Total assets * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
2.42
9.95
-0.47
6.73
-3.24
Peer Median
2.69
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Margin

22.60

Higher than Peers by 9.74

Operating profit (EBIT) / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
22.60
59.29
3.32
48.98
19.27
Peer Median
12.86
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Margin

20.27

Higher than Peers by 12.80

Net profit / Total Income (Net sales plus other income) * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
20.27
46.42
-2.41
39.72
-17.00
Peer Median
7.47
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Profit Margin

0.00

--

(Net profit + Depreciation) / Gross Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
0.00
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Revenue Growth

1.03

Lower than Peers by 7.52

Year on year growth in net sales

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
1.03
0.60
0.27
-0.33
-0.19
Peer Median
8.55
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EBIT Growth

-12.91

Lower than Peers by 21.05

Year on year growth in operating profit (EBIT)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
-12.91
2,761.57
-91.36
70.10
-58.82
Peer Median
8.14
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Net Profit Growth

5.93

Lower than Peers by 0.68

Year on year growth in profit after tax

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
5.93
3,186.63
-107.73
256.33
-158.39
Peer Median
6.61
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EPS Growth

7.91

Lower than Peers by 0.94

Year on year growth in earnings per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
7.91
28.71
-1.07
2.49
-1.58
Peer Median
8.85
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Book Value Growth

4.60

Lower than Peers by 0.80

Year on year growth in book value per share

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
4.60
--
--
--
--
Peer Median
5.40
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Debt to Equity

0.71

Higher than Peers by 0.27

Total debt / Net worth

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
0.71
0.44
0.01
0.01
0.15
Peer Median
0.44
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Short term debt to equity ratio

0.47

--

(Short term borrowings / Net worth)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
0.47
0.00
0.00
0.00
0.13
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Current Ratio

1.22

Lower than Peers by 0.64

Current Assets / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
1.22
22.23
8.93
14.15
2.67
Peer Median
1.86
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Quick Ratio

1.19

Lower than Peers by 0.15

(Current Assets - Inventory) / Current Liabilities and Provisions

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
1.19
21.98
8.55
12.72
2.53
Peer Median
1.34
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Interest Coverage

7.45

Higher than Peers by 1.29

Earning before interest and taxes (EBIT) / Interest Expenses

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
7.45
33.71
1.83
98.04
21.02
Peer Median
6.15
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Operating Efficiency

View Detailed Peer Comparison

Debtors to sales

42.36

Higher than Peers by 21.07

Debtors outstanding / Net Sales * 100

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
42.36
22.77
25.40
29.94
17.85
Peer Median
21.29
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Asset Turnover

0.12

Lower than Peers by 0.29

Sales / Average Total Assets

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
0.12
0.21
0.19
0.17
0.19
Peer Median
0.41
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Receivable days

--

--

Average Debtors / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
--
70.50
89.34
103.40
117.89
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Inventory Days

--

--

Average Inventory / Sales * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
--
644.28
628.04
194.16
140.42
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Payable days

--

--

Average Creditors / Cost of goods sold * 365

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
--
234.84
126.32
40.30
47.40
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Cash Conversion Cycle

--

--

Receivable Days + Inventory Days - Payable Days

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
--
479.94
591.06
257.26
210.92
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Earnings

124.01

Higher than Peers by 69.17

Current share price divided by earning per share in the last twelve months

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
124.01
32.11
-504.23
24.21
-33.82
Peer Median
54.84
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Price / Book Value

6.58

Lower than Peers by 0.70

Current share price divided by book value per share in the latest financial year

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
6.58
3.93
2.45
1.80
1.89
Peer Median
7.27
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Dividend Yield

--

--

Dividend per share in the past twelve months divided by current share price

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
--
--
--
--
--
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
EV/EBITDA

73.08

--

Enterprise Value (Current Market Capitalisation + Total Debt - Cash & Equivalents) / Earnings before interest, taxes, depreciation and taxes (EBITDA)

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
73.08
19.27
43.73
10.89
12.37
Peer Median
--
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
Market Cap

6,177

Higher than Peers by 4,651

Current Share price multiplied by latest total number of shares outstanding

Company Name
TTM
Dec-25
Dec-24
Dec-23
Dec-22
Ligand Pharmaceuticals (LGND)
6,177
--
--
--
--
Peer Median
1,525
--
--
--
--
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...